On April 14, 2025, Cue Biopharma, Inc. entered into an underwriting agreement for a public offering of approximately 13.5 million shares of common stock and warrants, expecting to raise about $18 million in net proceeds. As of March 31, 2025, the company estimated it had $13.1 million in cash and cash equivalents, which, along with the offering proceeds, should fund operations into the second quarter of 2026.